Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment

Scandinavian Journal of Rheumatology

Volumn 38, Issue 1, 2009, Pages 23-27

  Shirinsky, I V ^a   Zheltova, O I ^a   Solovyova, N Y ^a   Kozlov, V A ^a   Shirinsky, V S ^a  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; LIVER FUNCTION TEST; MALE; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; UPREGULATION;

AGED; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-10; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61649093065     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802363776     Document Type: Article

References (15)

1. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.
2. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
3. Kanda H, Hamasaki K, Kubo K, Tateishi S, Yonezumi A, Kanda Y, et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 2002;29:2024-6.
4. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-11.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
6. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
7. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
8. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4489-96.
9. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
10. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
11. Kim HR, Kim HS, Park MK, Cho ML, Lee SH, Kim HY. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 2007;36:259-64.
12. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, Naruszewicz M. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci 2004;75:1287-302.
13. Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006;176:5284-92.
14. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
15. Morita Y, Fukazawa T, Hirashima M, Kaga K, Kusaoi M, Morita T, et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006;35:268-72.